PERRIGO COMPANY PLC
Ownership & governance
Executives 5Directors 10Avg age 60Avg tenure 4.4y
AM
Albert Manzone
Chief Executive Officer
Age 63Since 2026-06-06Profile →
+14
Executives5
AM
Albert Manzone→
Chief Executive Officer
Age 63Since 2026-06-06
EB
Eduardo Bezerra→
Director of Finance/CFO
Age 51Since 2022-05-15
MW
Matt Winterman→
Chief Operating Officer
—Since 2025-06-22
AL
Abbie Lennox→
Chief Tech/Sci/R&D Officer
Age 45Since 2025-01-05
BJ
Bradley Joseph→
Investor Relations Contact
—Since 2011-06-30
Board of directors10
DO
Donal O'Connor→
Director/Board Member
Age 75Since 2014-10-31
GP
Geoffrey Parker→
Director/Board Member
Age 61Since 2016-11-06
BA
Bradley Alford→
Director/Board Member
Age 70Since 2017-02-05
OA
Orlando Ashford→
Chairman
Age 57—
AM
Albert Manzone→
Director/Board Member
Age 63Since 2022-07-29
JB
Julia Brown→
Director/Board Member
Age 56Since 2023-10-31
JS
Jonas Samuelson→
Director/Board Member
Age 58Since 2025-01-14
KE
Kevin Egan→
Director/Board Member
Age 60Since 2025-04-30
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| BlackRock Advisors LLC | 11.93 % | 16,501,498 |
| T. Rowe Price Associates, Inc. (IM) | 10.13 % | 14,016,148 |
| T. Rowe Price International Ltd. | 9.668 % | 13,376,776 |
| LB Hercules Holdings LLC | 7.56 % | 10,460,080 |
| Vanguard Portfolio Management LLC | 5.884 % | 8,141,919 |
Catalog · 2026-07-09
SEC officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Abbie Lennox | Chief Tech/Sci/R&D Officer | — | - |
| Albert A. Manzone | Interim President and Chief Executive Officer | — | - |
| Eduardo Bezerra | Director of Finance/CFO | — | - |
| Matt Winterman | Chief Operating Officer | — | - |
| Orlando Ashford | Chairman | — | - |
| A. Amin | Director/Board Member | — | - |
| Albert Manzone | Director/Board Member | — | - |
| Bradley Alford | Director/Board Member | — | - |
SEC · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| Galpharm International Ltd. | Pharmaceuticals: Major |
| Galpharm International Ltd. | Pharmaceuticals: Major |
| Perrigo UK Acquisition Ltd. | Miscellaneous Commercial Services |
| Perrigo UK Acquisition Ltd. | Miscellaneous Commercial Services |
| Wrafton Laboratories Ltd. | Pharmaceuticals: Other |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus noneMean target 16.5Range 14–20Analysts 4
14Mean 16.520
- Strong buy 1
- Buy 1
- Hold 3
Broker actions40 of 166
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Buy | 17 | 2026-02-27 |
| JP Morgan | Maintained | Neutral | 18 | 2025-12-15 |
| Canaccord Genuity | Maintained | Buy | 20 | 2025-11-06 |
| JP Morgan | Downgrade | Neutral | 20 | 2025-11-06 |
| Jefferies | Maintained | Hold | 23 | 2025-10-27 |
| Canaccord Genuity | Maintained | Buy | 40 | 2025-08-07 |
| JP Morgan | Maintained | Overweight | 35 | 2025-08-07 |
| Piper Sandler | Downgrade | Neutral | 27 | 2025-01-06 |
| Canaccord Genuity | Maintained | Buy | 42 | 2024-09-30 |
| Jefferies | Downgrade | Hold | 30 | 2024-09-23 |
| Piper Sandler | Maintained | Overweight | 35 | 2024-07-11 |
| Piper Sandler | Maintained | Overweight | 36 | 2024-06-13 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.